Logo image of ETNB

89BIO INC (ETNB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ETNB - US2825591033 - Common Stock

14.84 USD
0 (0%)
Last: 10/29/2025, 8:26:03 PM
14.95 USD
+0.11 (+0.74%)
After Hours: 10/29/2025, 8:26:03 PM
Fundamental Rating

2

Overall ETNB gets a fundamental rating of 2 out of 10. We evaluated ETNB against 533 industry peers in the Biotechnology industry. The financial health of ETNB is average, but there are quite some concerns on its profitability. ETNB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ETNB had negative earnings in the past year.
In the past year ETNB has reported a negative cash flow from operations.
In the past 5 years ETNB always reported negative net income.
In the past 5 years ETNB always reported negative operating cash flow.
ETNB Yearly Net Income VS EBIT VS OCF VS FCFETNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -74.60%, ETNB is doing worse than 65.30% of the companies in the same industry.
Looking at the Return On Equity, with a value of -86.29%, ETNB is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA -74.6%
ROE -86.29%
ROIC N/A
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
ETNB Yearly ROA, ROE, ROICETNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ETNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETNB Yearly Profit, Operating, Gross MarginsETNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

ETNB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ETNB has been increased compared to 5 years ago.
Compared to 1 year ago, ETNB has a worse debt to assets ratio.
ETNB Yearly Shares OutstandingETNB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ETNB Yearly Total Debt VS Total AssetsETNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ETNB has an Altman-Z score of 12.41. This indicates that ETNB is financially healthy and has little risk of bankruptcy at the moment.
ETNB has a better Altman-Z score (12.41) than 85.45% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that ETNB is not too dependend on debt financing.
ETNB has a worse Debt to Equity ratio (0.07) than 62.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 12.41
ROIC/WACCN/A
WACCN/A
ETNB Yearly LT Debt VS Equity VS FCFETNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 15.19 indicates that ETNB has no problem at all paying its short term obligations.
The Current ratio of ETNB (15.19) is better than 90.86% of its industry peers.
ETNB has a Quick Ratio of 15.19. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.
ETNB has a Quick ratio of 15.19. This is amongst the best in the industry. ETNB outperforms 90.86% of its industry peers.
Industry RankSector Rank
Current Ratio 15.19
Quick Ratio 15.19
ETNB Yearly Current Assets VS Current LiabilitesETNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

ETNB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -83.25%.
EPS 1Y (TTM)-83.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.74% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.68%
EPS Next 2Y13.7%
EPS Next 3Y10.47%
EPS Next 5Y12.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ETNB Yearly Revenue VS EstimatesETNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
ETNB Yearly EPS VS EstimatesETNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ETNB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ETNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ETNB Price Earnings VS Forward Price EarningsETNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETNB Per share dataETNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.7%
EPS Next 3Y10.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ETNB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

89BIO INC

NASDAQ:ETNB (10/29/2025, 8:26:03 PM)

After market: 14.95 +0.11 (+0.74%)

14.84

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners110.73%
Inst Owner Change-5.76%
Ins Owners0.55%
Ins Owner Change-22563.9%
Market Cap2.20B
Revenue(TTM)N/A
Net Income(TTM)-450.21M
Analysts80
Price Target29.52 (98.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.44%
Min EPS beat(2)-42.32%
Max EPS beat(2)3.43%
EPS beat(4)1
Avg EPS beat(4)-45.24%
Min EPS beat(4)-112.45%
Max EPS beat(4)3.43%
EPS beat(8)4
Avg EPS beat(8)-20.08%
EPS beat(12)6
Avg EPS beat(12)-10.39%
EPS beat(16)8
Avg EPS beat(16)-10.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.76%
EPS NQ rev (1m)-1.31%
EPS NQ rev (3m)3.49%
EPS NY rev (1m)-0.97%
EPS NY rev (3m)-2.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.22
P/tB 4.22
EV/EBITDA N/A
EPS(TTM)-3.61
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-2.96
FCFYN/A
OCF(TTM)-2.96
OCFYN/A
SpS0
BVpS3.51
TBVpS3.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.6%
ROE -86.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.19
Quick Ratio 15.19
Altman-Z 12.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)20.59%
Cap/Depr(5y)70.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-83.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.92%
EPS Next Y34.68%
EPS Next 2Y13.7%
EPS Next 3Y10.47%
EPS Next 5Y12.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-143.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.72%
EBIT Next 3Y-6.97%
EBIT Next 5YN/A
FCF growth 1Y-312.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-312.53%
OCF growth 3YN/A
OCF growth 5YN/A

89BIO INC / ETNB FAQ

What is the ChartMill fundamental rating of 89BIO INC (ETNB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ETNB.


What is the valuation status for ETNB stock?

ChartMill assigns a valuation rating of 0 / 10 to 89BIO INC (ETNB). This can be considered as Overvalued.


Can you provide the profitability details for 89BIO INC?

89BIO INC (ETNB) has a profitability rating of 0 / 10.